| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
16,352 |
8,086 |
$84K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
3,784 |
2,489 |
$59K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
764 |
514 |
$51K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,423 |
6,051 |
$41K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,938 |
1,841 |
$38K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,804 |
1,209 |
$33K |
| 11721 |
|
5,497 |
2,664 |
$28K |
| 99310 |
Prolong nursin fac eval 15m |
1,140 |
966 |
$28K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
4,312 |
1,404 |
$24K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
3,154 |
1,058 |
$24K |
| 80053 |
Comprehensive metabolic panel |
5,955 |
5,408 |
$21K |
| 99215 |
Prolong outpt/office vis |
2,645 |
1,399 |
$19K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
1,168 |
946 |
$14K |
| 51798 |
|
492 |
479 |
$13K |
| 99336 |
|
354 |
311 |
$11K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,531 |
3,386 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,456 |
3,309 |
$9K |
| 90832 |
Psychotherapy, 30 minutes with patient |
3,149 |
1,563 |
$8K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,152 |
6,293 |
$8K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
489 |
420 |
$7K |
| 52000 |
|
148 |
74 |
$6K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,381 |
2,086 |
$6K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,074 |
524 |
$6K |
| 36415 |
Collection of venous blood by venipuncture |
12,602 |
10,461 |
$6K |
| 99337 |
|
184 |
168 |
$6K |
| Q3014 |
Telehealth originating site facility fee |
2,955 |
1,815 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
158 |
141 |
$5K |
| 76775 |
|
198 |
120 |
$5K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
498 |
250 |
$4K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,200 |
1,154 |
$3K |
| 82607 |
|
611 |
585 |
$3K |
| 83735 |
|
1,829 |
1,596 |
$2K |
| 80061 |
Lipid panel |
2,984 |
2,885 |
$2K |
| 85610 |
|
1,249 |
700 |
$2K |
| 81003 |
|
1,375 |
1,265 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
721 |
660 |
$1K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,159 |
1,054 |
$1K |
| 87077 |
|
379 |
340 |
$1K |
| A0425 |
Ground mileage, per statute mile |
50 |
44 |
$1K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
3,219 |
1,114 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
623 |
574 |
$1K |
| 99335 |
|
30 |
30 |
$1K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
532 |
479 |
$1K |
| 82728 |
|
375 |
346 |
$1K |
| 82043 |
|
324 |
311 |
$1K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
68 |
64 |
$984.72 |
| 83540 |
|
728 |
676 |
$966.82 |
| 98928 |
|
100 |
44 |
$876.47 |
| 97161 |
|
74 |
72 |
$868.69 |
| 85027 |
|
484 |
457 |
$824.80 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
26 |
13 |
$751.32 |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
195 |
146 |
$747.12 |
| 90837 |
Psychotherapy, 53 minutes with patient |
173 |
118 |
$722.69 |
| 90834 |
Psychotherapy, 45 minutes with patient |
422 |
295 |
$697.12 |
| 99327 |
|
20 |
20 |
$480.62 |
| 81001 |
|
328 |
285 |
$410.26 |
| 83550 |
|
283 |
261 |
$398.42 |
| 99305 |
|
19 |
16 |
$385.66 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
1,090 |
1,017 |
$380.03 |
| 85652 |
|
203 |
195 |
$288.05 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
31 |
25 |
$249.41 |
| 82570 |
|
64 |
61 |
$220.48 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
140 |
133 |
$195.47 |
| 97035 |
|
37 |
12 |
$180.40 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
352 |
302 |
$180.17 |
| 86140 |
|
71 |
64 |
$165.84 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
524 |
506 |
$154.51 |
| 83690 |
|
160 |
138 |
$152.09 |
| 90662 |
|
267 |
260 |
$144.56 |
| G0008 |
Administration of influenza virus vaccine |
989 |
962 |
$122.77 |
| 84439 |
|
34 |
32 |
$109.24 |
| 11055 |
|
26 |
12 |
$100.68 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
26 |
12 |
$99.05 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
32 |
27 |
$97.37 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
67 |
67 |
$94.75 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
29 |
29 |
$91.06 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
189 |
92 |
$89.10 |
| 95886 |
|
14 |
14 |
$78.31 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
58 |
25 |
$78.29 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
17 |
17 |
$71.71 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
92 |
88 |
$67.85 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
858 |
797 |
$58.52 |
| 87205 |
|
14 |
13 |
$50.29 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
85 |
80 |
$31.70 |
| 99442 |
|
27 |
25 |
$26.60 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
33 |
25 |
$16.45 |
| 90658 |
|
152 |
143 |
$12.62 |
| 84484 |
|
13 |
12 |
$8.40 |
| 0124A |
|
14 |
14 |
$6.94 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
59 |
56 |
$6.69 |
| 84600 |
|
83 |
81 |
$1.78 |
| 80076 |
|
12 |
12 |
$1.67 |
| 90686 |
|
169 |
168 |
$0.00 |
| 0064A |
|
28 |
28 |
$0.00 |
| 0001A |
|
565 |
541 |
$0.00 |
| 0031A |
|
42 |
34 |
$0.00 |
| A9270 |
Non-covered item or service |
47 |
42 |
$0.00 |
| 0134A |
|
17 |
16 |
$0.00 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
34 |
28 |
$0.00 |
| 90480 |
|
16 |
16 |
$0.00 |
| 0011A |
|
123 |
122 |
$0.00 |
| 0012A |
|
132 |
130 |
$0.00 |
| 91300 |
|
650 |
548 |
$0.00 |
| 81025 |
|
13 |
12 |
$0.00 |
| Q2038 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) |
28 |
28 |
$0.00 |
| 0002A |
|
537 |
513 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
25 |
25 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
32 |
16 |
$0.00 |
| 0004A |
|
48 |
47 |
$0.00 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
30 |
14 |
$0.00 |
| 91320 |
|
16 |
16 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
28 |
28 |
$0.00 |
| 0071A |
|
13 |
13 |
$0.00 |